Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2016 Sep 15;6:33530. doi: 10.1038/srep33530

Anion channelrhodopsins for inhibitory cardiac optogenetics

Elena G Govorunova 1, Shane R Cunha 2, Oleg A Sineshchekov 1, John L Spudich 1,a
PMCID: PMC5024162  PMID: 27628215

Abstract

Optical control of the heart muscle is a promising strategy for cardiology because it is more specific than traditional electrical stimulation, and allows a higher temporal resolution than pharmacological interventions. Anion channelrhodopsins (ACRs) from cryptophyte algae expressed in cultured neonatal rat ventricular cardiomyocytes produced inhibitory currents at less than one-thousandth of the light intensity required by previously available optogenetic tools, such as the proton pump archaerhodopsin-3 (Arch). Because of their greater photocurrents, ACRs permitted complete inhibition of cardiomyocyte electrical activity under conditions in which Arch was inefficient. Most importantly, ACR expression allowed precisely controlled shortening of the action potential duration by switching on the light during its repolarization phase, which was not possible with previously used optogenetic tools. Optical shortening of cardiac action potentials may benefit pathophysiology research and the development of optogenetic treatments for cardiac disorders such as the long QT syndrome.


Manipulation of the membrane potential by light using genetically encoded microbial rhodopsins (optogenetics) enables control of defined cell populations1,2. Therefore optogenetic gene therapy could provide a more targeted and less invasive alternative for cardiomodulation than implanted electrical devices or pharmaceuticals3,4,5. Whereas cardiac pacing by light depends on membrane-depolarizing, excitatory optogenetics tools6,7,8, in cardiology there is also a need for hyperpolarizing, inhibitory molecules. Transgenically expressed halorhodopsin (NpHR) was used to identify pacemaker regions in the zebrafish heart9. However, NpHR and other rhodopsin ion pumps transport only one charge per captured photon, which makes them relatively inefficient silencing tools10. Recently channelrhodopsins with strict anion selectivity and high unitary conductance (anion channelrhodopsins, or ACRs) have been discovered in cryptophyte algae and used for neuronal inhibition at much lower light intensities than rhodopsin ion pumps and Cl-conducting mutants of cation channelrhodopsins11.

Here we test the performance of ACRs from Guillardia theta (GtACRs) as tools for inhibition of cardiomyocyte electrical activity and compare them side by side with the proton pump archaerhodopsin-3 (Arch)12, previously used for this purpose13. Our choice of this pump for comparison with GtACRs was motivated by the observation that Arch generated larger hyperpolarizing photocurrents than NpHR when measured in the same heterologous system12,14. We show that GtACRs generated larger photocurrents than Arch when expressed in cultured cardiomyocytes. Complete inhibition of electrical activity was observed in GtACR-expressing cardiomyocytes at a light intensity which resulted in only a small decrease in the frequency of spiking in Arch-expressing cells. Moreover, by threshold-based closed-loop optogenetics in cardiomyocytes expressing GtACRs we could accelerate repolarization and precisely terminate action potentials at any time during their repolarization phase, which, to the best of our knowledge, has not been previously demonstrated.

Results

We expressed the transmembrane domains of GtACR1, GtACR2 and Arch fused to C-terminal enhanced yellow fluorescence protein (EYFP) under the mouse ubiquitin C promoter in cultured neonatal rat ventricular cardiomyocytes (NRVMs) using lentiviral delivery. The position of the maximal absorption wavelength of GtACR1 (515 nm) is red-shifted compared to that of GtACR2 (470 nm), which is advantageous because it allows using light stimuli of higher penetration depth. Therefore, we chose GtACR1 for comparison with Arch. Expression of both constructs in cardiomyocytes was confirmed by immunofluorescent microscopy (Fig. 1).

Figure 1. Expression of Arch or GtACR1 in cultured NRVMs.

Figure 1

Confocal immunofluorescence images of uninfected NRVMs (top row), transduced with Arch (middle row) and transduced with GtACR1 (bottom row). EYFP tag fluorescence is shown in the left column (green channel), the cardiomyocyte marker (MYBPC3, myosin binding protein C-3) fluorescence is shown in the middle column (red channel), and merged images are shown in the right column.

First, we characterized photocurrents generated by Arch and GtACR1 by whole-cell voltage clamp of individual NRVMs. Figure 2a,b show series of hyperpolarizing photocurrents recorded from cells expressing Arch and GtACR1, respectively, evoked by a 1-s light pulse of varied intensity. The mean peak amplitude of GtACR1 photocurrents was ~12 fold greater than that of Arch currents, although the expression level of the former, assessed by measuring the tag fluorescence, was ~3 fold lower (Fig. 2c). The current rise and decay rates are shown in Fig. 2d. The membrane hyperpolarization is proportional to the amount of charge transported across the membrane. Figure 2e shows the dependence of charge transported during 1 s of illumination on the light intensity measured in cells expressing Arch or GtACR1. Almost 4 orders of magnitude less light was needed to reach the same value for GtACR1 than for Arch. The amplitude of Arch currents showed a weak voltage dependence, whereas that of GtACR1 currents was very steep (Fig. 2f), making the latter protein a dynamic hyperpolarizing tool at membrane potentials above the Nernst equilibrium potential for Cl.

Figure 2. Photocurrents generated by Arch and GtACR1 in cultured NRVMs.

Figure 2

(a,b) Series of photocurrents generated by Arch (a) and GtACR1 (b) at 0 mV voltage at the amplifier output in response to 1-s light pulses shown as the colored bars on top. The wavelength was 560 nm for Arch and 510 nm GtACR1; the numbers show the intensity in mW mm−2. (c) The peak amplitude of photocurrents at 0 mV at the amplifier output at 6.7 mW mm−2 light intensity (solid bars, left axis) and relative tag fluorescence normalized for the membrane area (hatched bars, right axis). Error bars, sem (n = 5 cells). (d) The half-rise (solid bars, left axis) and half-decay rates of photocurrents (hatched bars, right axis). Error bars, sem (n = 5 cells). (e) The dependence of the amount of charge transported across the membrane during 1-s illumination on the stimulus intensity. Error bars, sem (n = 5 cells). (f) The current-voltage dependence under standard conditions (bath: [Cl] 135 mM, pH 7.3; pipette: [Cl] 4 mM, pH 7.2; other components see in Methods). Error bars, sem (n = 3 cells).

To test the performance of Arch and GtACR1 as tools for inhibition of cardiomyocyte function without perturbing the intracellular ion concentrations, we used extracellular recording from star-shaped aggregates of synchronously beating cells in growth medium. Expression of either Arch or GtACR1 did not change the frequency of APs in the dark, which was 67 ± 3 (mean ± sem; n = 11 cell clusters) and 68 ± 3 (mean ± sem; n = 29 cell clusters) APs/min, respectively, compared to 65 ± 2 (mean ± sem; n = 6 cell clusters) for control (uninfected) NRVMs. In cells expressing Arch switching on the light resulted in immediate suppression of electrical activity, but it was resumed at irregular intervals during a 30-s illumination period even at the highest intensity used (6.7 mW mm−2; Fig. 3a). In cells expressing GtACR1 illumination caused a decrease in AP amplitude; 50% inhibition was observed at ~10 μW mm−2 (Fig. 3b). Figure 3c summarizes the results obtained with Arch- and GtACR1-expressing cells. In control (uninfected) NRVMs both the AP frequency and amplitude were unaffected by light even at the maximal intensity: 96 ± 3% and 108 ± 6%, respectively, as compared to the previous dark period (mean ± sem; n = 6 cell clusters). Normal electrical activity of the GtACR1-expressing culture restored within 2.0 ± 0.4 s at 7.7 mW mm−2 (mean ± sem; n = 6 cell clusters) and 1.5 ± 0.2 s at 0.7 mW mm−2 (mean ± sem; n = 5 cell clusters) after switching off the light of the maximal intensity. In Arch-expressing NRVMs no significant increase in AP frequency was observed after switching off the light relative to the preillumination period, in contrast to the results obtained in cardiomyocytes electrically coupled to Arch-expressing human embryonic kidney (HEK293) cells13.

Figure 3. Photoinhibition of electrical activity of cultured NRVMs transduced with Arch or GtACR1.

Figure 3

(a,b) Extracellular voltage recording from cell clusters expressing Arch (a) or GtACR1 (b) normalized to the mean value of the AP amplitude recorded before the onset of illumination. The 30-s light pulse is schematically shown as the colored bar on top. The numbers show the light intensity in mW mm−2. (c) The light dependence of AP number during the illumination period relative to the previous dark period (left axis, empty symbols) and AP amplitude (right axis, filled symbols) cells expressing Arch (black) and GtACR1 (red). Error bars, sem (n = 5–9 cells).

GtACR2 also generated robust photocurrents in NRVMs (Fig. 4a), but more light was required to achieve the same degree of AP inhibition as compared to GtACR1-expressing cells (Fig. 4b, hatched bars). The decay rate of GtACR2-generated photocurrent at 0 mV was 0.019 ± 0.004 ms−1 (n = 5 cells), i.e., ~2 fold higher than that of GtACR1-generated currents (Fig. 2d). We also compared AP inhibition in GtACR1- and GtACR2-expressing cells by patch clamp recording in the current clamp mode. For both proteins, the light sensitivity probed by patch clamping was higher than that determined noninvasively by extracellular recording (Fig. 4b, solid bars), which can be explained by a steeper Cl gradient used in patch clamp experiments. Measurements of the intracellular Cl concentration in the heart muscle by ion-selective microelectrodes yielded values from 14 to 20 mM depending on the animal species, cell type and developmental stage15,16,17. We tested the dependence of the photocurrent amplitude and the reversal potential (Erev) on the Cl concentration in the pipette. When it was increased from 4 to 40 mM, the Erev followed the Nernst equilibrium potential for Cl, as expected, which resulted in ~2-fold reduction of the photocurrents (Supplementary Fig. S1).

Figure 4. Photocurrents generated by GtACR2 and comparison of the efficiency of photoinhibition of AP generation by GtACR1 and GtACR2.

Figure 4

(a) A series of photocurrents generated by GtACR2 at 0 mV voltage at the amplifier output in response to 1-s light pulses shown as the colored bars on top. The wavelength was 470 nm; the numbers show the intensity in mW mm−2. (b) Comparison of the light intensities required for 50% inhibition of AP amplitude in NRVMs expressing GtACR1 or GtACR2 determined by extracellular recording (hatched bars) or whole-cell patch clamp in current clamp mode (solid bars). Error bars, sem (n = 3–9 cells).

Besides complete silencing of cardiac electrical activity, optogenetics can potentially be used for shaping AP morphology18. In particular, changing the AP duration (APD) is desired for probing and potentially curing pathological conditions resulting from APD abnormalities, such as the life-threatening long QT syndrome, which results from an abnormally slow repolarization phase of the AP19. To explore the possibility of optical shortening of the APD, we delivered light pulses at different times during an ongoing spontaneous AP using threshold-based closed-loop control. Expression of GtACRs did not significantly influence the APD at 50% repolarization (APD50) measured in the dark (272 ± 34, 270 ± 32 and 269 ± 21 ms in control, GtACR1- and GtACR2-expressing cells, respectively; n = 5–7 cells). When light was switched on during the depolarization phase, it resulted in cutting off the nascent AP (Supplementary Fig. S2), as was previously observed using NpHR20. Moreover, GtACRs permitted temporally precise truncation of the AP at any time point during the repolarization phase (Fig. 5a and Supplementary Fig. S2), which could not be achieved with NpHR20. Variation of the light intensity allowed fine tuning of the AP shape (Fig. 5b,c). The AP amplitude in experiments in which the light was switched on during the repolarization phase was 100 ± 0.8% (mean ± sem, n = 13 recordings) as compared to that measured in the dark.

Figure 5. Optical shortening of APs in cultured NRVMs expressing GtACR1.

Figure 5

(a,b) Normalized APs recorded from NRVMs expressing GtACR1 in the dark (black lines) and upon illumination (colored lines) with 510-nm light shown as green bars. In (a) the light pulse (77 μW mm−2) was delivered at different times during the repolarization phase of the AP. In (b) the light pulses of varied intensity (numbers in the legend, in μW mm−2) were delivered at the same time point. (c) Ensemble data from experiments as in panel (b). The APD50 fraction from the onset of the light was measured and divided by the value measured from the same time point in the dark. Error bars, sem (n = 5 APs). The line is a Lorentz function approximation.

Discussion

In previous studies the proton-pumping rhodopsin Arch was used to suppress cardiomyocyte electrical activity via cell delivery, i.e. by coupling of Arch-expressing HEK293 cells to cardiomyocytes13. We showed that AP generation could be suppressed immediately after switching on the light upon lentiviral expression of Arch in cardiomyocytes, but it resumed at irregular intervals during the 30-s illumination period even at the highest light intensity used (6.7 mW mm−2). Expression of the chloride-pumping rhodopsin NpHR enabled inhibition of individual cardiac APs by short light pulses of lower intensity, but the activity was not monitored for longer illumination periods20. For a complete suppression of AP generation during several seconds with NpHR a light intensity of 30 mW mm−2 was required9.

GtACRs generated much larger currents and permitted AP inhibition at much lower light intensities than Arch. In addition to conducting many ions per photocycle in contrast to only one transported by rhodopsin ion pumps such as Arch or NpHR, ACRs also become more efficient upon the membrane depolarization (e.g. during the depolarization phase of an AP) because of the steep voltage dependence of their currents. Unlike rhodopsin ion pumps, ACRs transport ions passively, i.e., they generate hyperpolarizing currents only above the Nernst equilibrium potential for Cl. This means that their efficiency as optogenetic silencing tools will depend on the intracellular Cl concentration which may vary between species, cell types and other conditions. Nevertheless, currents generated by GtACR1 at 40 mM Cl in the pipette (which is twice as high as the intracellular Cl- concentration measured in the heart with ion-selective microelectrodes15) were still ~5 fold larger than maximal Arch photocurrents. Furthermore, our data obtained by extracellular recording unambiguously demonstrated that complete inhibition of cardiomyocyte electrical activity by light could be achieved at physiological intracellular Cl concentrations.

The potentially most attractive application of GtACRs in optogenetics is their use for temporally precise truncation of APs during the repolarization phase. In a previous study NpHR failed to deliver this benefit20. Moreover, shortening of the AP duration observed when the light pulse was delivered during the depolarization phase was accompanied by a reduction of the AP amplitude20. Therefore, the results obtained with NpHR are better described as AP inhibition rather than AP shaping.

Shortening of the AP duration to treat the long QT syndrome appears to be a therapeutic therapeutic goal for which ACRs are particularly suitable. Using intensity-modulated rather than continuous light stimuli may help recreate more realistic morphology of shortened APs. Although continuous illumination of ACR-expressing cardiomyocytes led to a decrease in the AP amplitude rather than frequency (Fig. 3c), potentially closed-loop optogenetics can also be used to reduce the frequency by imposing a desired refractory period after each AP, which can lead to the development of novel therapeutic treatments for tachyarrhythmias.

A disadvantage of GtACRs as compared to rhodopsin ion pumps is a slower decay rate of their photocurrents. It is of little importance when a complete inhibition of cardiac electrical activity for an extended period of time is required (i.e., for analysis of the heart conduction system as in ref. 9). GtACR2 exhibits ~2 fold faster photocurrent decay compared to GtACR1 and is therefore more suitable for the latter goal. Screening of natural ACR variants from other cryptophyte algae and/or molecular engineering of known ACRs is desirable for improving their temporal resolution.

Methods

Expression constructs

The polynucleotide sequences encoding the seven-transmembrane (7TM) domains of GtACR1 (295 amino acid residues), GtACR2 (291 amino acid residues) and Arch (a gift of E.S. Boyden; 258 amino acid residues) were subcloned to the pFUGW vector backbone21 in frame with an enhanced yellow fluorescence protein (EYFP) tag and verified by sequencing.

Neonatal rat ventricular cardiomyocyte isolation and transduction

Cardiomyocytes were isolated following the procedure as previously described22. In accordance with the animal protocol approved by the Animal Welfare Committee at University of Texas Health Science Center at Houston, 1-2 day old Sprague-Dawley rat pups were euthanized by decapitation. Hearts were exposed, excised, minced, and digested through a series of agitations in buffer containing collagenase type II (Worthington, Collagenase type II 305 U/mg) and pancreatin (Sigma). Cells from each digestion were collected and pooled, and pre-plated on Nunc plates (Thermo Fisher Scientific) in Complete Medium (40% DMEM, 40% Ham’s F-10, 20% fetal calf serum) for 2–4 hours to reduce fibroblasts and enrich for cardiomyocytes. Following the pre-plate step, the non-adherent cells (cardiomyocytes) were aspirated from the plate, pelleted, resuspended in Complete Medium, and plated on coverslips or MatTek tissue culture plates (fibronectin-coated; Roche Applied Science). 36 hours later cardiomyocytes were washed with Ham’s F-10 and incubated with lentiviral preparations of Arch, GtARC1 or GtARC2 for 12–16 hours. Then, lentivirus was aspirated and the cardiomyocytes were maintained in Complete Medium before experiments were performed. Exogenous all-trans retinal (1 μM final concentration) was supplied immediately after transduction to improve light responsiveness of cardiac cells that express channelrhodopsins23.

Confocal immunofluorescence microscopy

48 hours after viral transduction, cardiomyocytes were fixed in 2% paraformaldehyde and incubated with primary antibodies overnight at 4 °C in 1XPBS containing 5% normal goat serum and 0.075% TritonX-100. Primary antibodies used were: MyBPC3 (1:250, Santa Cruz) and GFP (1:500, GF28R, Thermo Scientific). Secondary antibodies used were donkey anti-mouse conjugated to Alexa Fluor 488 and donkey anti-rabbit conjugated to Alexa Fluor 568 (1:500, LifeTechnologies). Images were obtained with a Nikon A1 confocal microscope (Nikon, Melville, NY) equipped with 40x oil, numerical aperture 1.3 objective.

Fluorescence measurements

EYFP fluorescence was measured with a CoolSnap HQ2 CCD camera (Photometrics, Tucson, AZ) using a Nikon Eclipse Ti-U microscope. Excitation was from an X-Cite 120Q light source (EXFO, Mississauga, Ontario), and fluorescence was detected using a Nikon B-2E/C filter set. All images were taken with the same acquisition parameters and analyzed with the ImageJ1.42q software.

Patch clamp recording

Patch clamp measurements were performed on NRVMs 48–72 h after transduction using an Axopatch 200B amplifier (Molecular Devices, Union City, CA) at 25 °C. Only cells that spontaneously generated the action potentials (APs) were used for electrophysiological measurements. Such cells constituted ~90% in the culture, which confirmed the efficiency of the cardiomyocyte enrichment protocol. The signals were digitized with a Digidata 1440A using pClamp 10 software (both from Molecular Devices). Patch pipettes with resistances of 2–5 MΩ were fabricated from borosilicate glass. The Tyrode’s bath solution contained (in mM): NaCl 126, KCl 2, MgCl2 1, CaCl2 3, glucose 30, HEPES 25 (pH 7.3 adjusted with NaOH). The pipette solution contained, unless otherwise indicated, (in mM): K gluconate 135, MgCl2 2, HEPES 20 (pH 7.2). A 4 M salt bridge was used in all experiments. The current-voltages dependencies were corrected for liquid junction potentials calculated using the ClampEx built-in LJP calculator. Continuous light pulses were provided by a Polychrome IV light source (T.I.L.L. Photonics GMBH, Grafelfing, Germany) in combination with a mechanical shutter (Uniblitz Model LS6, Vincent Associates, Rochester, NY; half-opening time 0.5 ms). The light intensity was attenuated with the built-in Polychrome system or with neutral density filters. Maximal quantum density at the focal plane of the 40x objective lens was 7.7 mW/mm2 for 510-nm light and 6.7 mW/mm2 for 560-nm light. Threshold-based closed-loop control was implemented by triggering a 5-V pulse at ~95% of the AP peak to open the shutter after a time delay set by an S44 electrical stimulator (Grass Medical Instruments, Quincy, MA). Data were analyzed using pClamp 10 and Origin 7 (OriginLab Corporation, Northampton, MA) software.

Extracellular recording

Extracellular electrical recording was performed on clusters of synchronously beating NRVMs in the growth medium at 37 °C (controlled by an automatic temperature controller TC-324B, Warner Instruments Corporation, Hamden, CT) 7–10 days after transduction using the same equipment as described for patch clamping. The pipette was filled with the Tyrode’s solution and placed in the vicinity of a cell cluster so that it did not perturb its contraction. The electrical activity was recorded for 30 s in the dark to assess the baseline, after which a 30-s light pulse was applied followed by another 30-s dark period to monitor the recovery of beating after illumination. For analysis, the low-pass filter at 0.3 Hz and a high-pass filter at 3 Hz were applied to the recorded traces using pClamp 10.

Statistics

Statistical data are shown as mean ± sem. The n values in the legends indicate the number of independent experiments (individual cardiomyocytes or their clusters). For analysis of significance unpaired Student’s t-test was used, and p values less than 0.05 were considered significant.

Additional Information

How to cite this article: Govorunova, E. G. et al. Anion channelrhodopsins for inhibitory cardiac optogenetics. Sci. Rep. 6, 33530; doi: 10.1038/srep33530 (2016).

Supplementary Material

Supplementary Information
srep33530-s1.pdf (617.9KB, pdf)

Acknowledgments

We are grateful to Edward S. Boyden (Massachusetts Institute of Technology, Cambridge, MA, USA) for a gift of the Arch expression construct. This work was supported by NIH grant R01GM027750 and Endowed Chair AU-0009 from the Robert A. Welch Foundation.

Footnotes

The University of Texas Health Science Center at Houston listing J.L.S., E.G.G. and O.A.S. as inventors has filed patent applications regarding ACRs.

Author Contributions E.G.G. and J.L.S. conceived the study. S.R.C. performed NRVM isolation, transduction and confocal immunofluorescence microscopy. E.G.G. performed plasmid construction and electrophysiological measurements. O.A.S. assisted with experimental design and data analysis. All authors contributed to the discussion and preparation of the manuscript.

References

  1. Williams S. C. & Deisseroth K. Optogenetics. Proc. Natl. Acad. Sci. USA 110, 16287 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Deisseroth K. O.: 10 years of microbial opsins in neuroscience. Nat. Neurosci. 18, 1213–1225 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ambrosi C. M. & Entcheva E. Optogenetics’ promise: pacing and cardioversion by light? Future Cardiol. 10, 1–4 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boyle P. M., Karathanos T. V. & Trayanova N. A. “Beauty is a light in the heart”: the transformative potential of optogenetics for clinical applications in cardiovascular medicine. Trends Cardiovasc. Med. 25, 73–81 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Entcheva E. & Bub G. All-optical control of cardiac excitation: combined high-resolution optogenetic actuation and optical mapping. J. Physiol. 594, 2503–2510 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bruegmann T. et al. Optogenetic control of heart muscle in vitro and in vivo. Nat. Methods 7, 897–900 (2010). [DOI] [PubMed] [Google Scholar]
  7. Vogt C. C. et al. Systemic gene transfer enables optogenetic pacing of mouse hearts. Cardiovasc. Res. 106, 338–343 (2015). [DOI] [PubMed] [Google Scholar]
  8. Nussinovitch U. & Gepstein L. Optogenetics for in vivo cardiac pacing and resynchronization therapies. Nat. Biotechnol (2015). [DOI] [PubMed] [Google Scholar]
  9. Arrenberg A. B., Stainier D. Y., Baier H. & Huisken J. Optogenetic control of cardiac function. Science 330, 971–974 (2010). [DOI] [PubMed] [Google Scholar]
  10. Zhang F. et al. The microbial opsin family of optogenetic tools. Cell 147, 1446–1457 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Govorunova E. G., Sineshchekov O. A., Liu X., Janz R. & Spudich J. L. Natural light-gated anion channels: A family of microbial rhodopsins for advanced optogenetics. Science 349, 647–650 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chow B. Y. et al. High-performance genetically targetable optical neural silencing by light-driven proton pumps. Nature 463, 98–102 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nussinovitch U. & Gepstein L. Optogenetics for suppression of cardiac electrical activity in human and rat cardiomyocyte cultures. Neurophotonics 2, 031204 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Husson S. J. et al. Microbial light-activatable proton pumps as neuronal inhibitors to functionally dissect neuronal networks in C. elegans. PLoS One 7, e40937 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Vaughan-Jones R. D. Non-passive chloride distribution in mammalian heart muscle: micro-electrode measurement of the intracellular chloride activity. J. Physiol. 295, 83–109 (1979). [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Caille J. P., Ruiz-Ceretti E. & Schanne O. F. Intracellular chloride activity in rabbit papillary muscle: effect of ouabain. Am. J. Physiol. 240, C183–C188 (1981). [DOI] [PubMed] [Google Scholar]
  17. Baumgarten C. M. & Fozzard H. A. Intracellular chloride activity in mammalian ventricular muscle. Am. J. Physiol. 241, C121–C129 (1981). [DOI] [PubMed] [Google Scholar]
  18. Karathanos T. V., Boyle P. M. & Trayanova N. A. Optogenetics-enabled dynamic modulation of action potential duration in atrial tissue: feasibility of a novel therapeutic approach. Europace 16 Suppl 4, iv69-iv76 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wehrens X. H., Vos M. A., Doevendans P. A. & Wellens H. J. Novel insights in the congenital long QT syndrome. Ann. Intern. Med. 137, 981–992 (2002). [DOI] [PubMed] [Google Scholar]
  20. Park S. A., Lee S. R., Tung L. & Yue D. T. Optical mapping of optogenetically shaped cardiac action potentials. Sci. Rep. 4, 6125 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lois C., Hong E. J., Pease S., Brown E. J. & Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295, 868–872 (2002). [DOI] [PubMed] [Google Scholar]
  22. Wu H. C. et al. Identification and characterization of two ankyrin-B isoforms in mammalian heart. Cardiovasc. Res. 107, 466–477 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Yu J., Chen K., Lucero R. V., Ambrosi C. M. & Entcheva E. Cardiac optogenetics: Enhancement by all-trans-retinal. Sci. Rep. 5, 16542 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep33530-s1.pdf (617.9KB, pdf)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES